Mathilde/NLI4PR huggingface dataset:
Patient case (clinical description): A 15-year-old boy with mild intellectual disability is brought to the office by his parents for a routine physical examination.  The boy is going to a school for students with learning disabilities.  The patient was adopted, and his immunizations are up to date.  Review of the patient's medical records is notable for cytogenetic studies that showed a small gap near the tip of the long arm of the X chromosome, which is consistent with fragile X syndrome, an X-linked disorder. The defect is an unstable expansion of trinucleotide repeats (CGG) in the fragile X mental retardation 1 (FMR1) gene, located on the long arm of the X chromosome. He is not using any medications and vital signs are within normal levels. His blood chemistry analysis as bellow:
Blood Chemistry Value      Normal Range     Patient Value
Glucose                    90-120 mg/dl     95 mg/dl
BUN (Blood Urea Nitrogen)  7-24 mg/dl       10 mg/dl
Creatinine                 0.7-1.4 mg/dl    0.8 mg/dl
Calcium                    8.5-10.5 mg/dl   9 mg/dl
Sodium                     134-143 mEq/L    135 mEq/L
Potassium                  3.5-4.5 mEq/L    3.7 mEq/L
Chloride                   95-108 mEq/L     98 mEq/L
CO2                        20-30 mEq/L      25 mEq/L
Blood pH                   7.38-7.42        7. 39

Patient's own account: My husband and I brought our 15-year-old son to the clinic for his routine exam. My son is going to school for special needs students. We adopted him a few years ago. His vaccinations are up to date. He already passed some chromosome testing and they found that he has a fragile X syndrome. The doctor told us that it comes from repeats in the fragile X chromosome. My son is not using any medication and his blood pressure temperature and breathing were normal during the exam. He also did a blood test. The results came back and showed that his blood sugar urea creatinine calcium sodium potassium chloride CO2 and blood pH were all within the normal range.

Clinical trial: Development of a Resiliency Training Program for Parents of Children With Specific Learning Disabilities

Eligibility criteria:
Inclusion Criteria:

        Inclusion criteria for 3RP intervention:

          1. Being the parent of at least one elementary school aged child with a diagnosed
             specific learning disability

          2. Age 18 or older

        Exclusion Criteria:

        Exclusion criteria for participation in 3RP group:

          1. Being the parent of a child with a severe mental or physical disability up to the
             discretion of the principal investigator

          2. Unable or unwilling to sign the informed consent documents
No condition on gender to be admitted to the trial.
Accepts Healthy Volunteers
Subject must be at least 18 Years old.


Eligibility (NLI label): Contradiction
Patient case (clinical description): A 20-year-old man comes to the emergency due to bleeding after a tooth extraction.  The bleeding has persisted for approximately 30 minutes despite constant direct pressure.  He is a known case of Hemophilia type A treated with FVIII. Blood pressure is 95/60 mm Hg and pulse is 105/min. His weight is 70 Kg. Family history is positive for Hemophilia type A in his maternal uncle. He also has a lipoma on his left arm which he plans to remove surgically. His FVIII activity is 40%.

Patient's own account: I got my tooth extracted and I could not stop bleeding for 30 min. I'm a 20 yo dude but I have Hemophilia type A treated with FVIII. My blood pressure was 95/60 and my pulse 105/min. I'm 70 kg. My uncle on my mom's side also has type A hemophilia. I also have a fatty swelling on my left arm and I was supposed to remove it. My FVIII activity was 40%.

Clinical trial: Osteoporosis and Haemophilia

Eligibility criteria:
Inclusion Criteria:

          -  Adult patients (≥ 18 years of age) suffering from mild (FVIII or IX >5 %), moderate
             (FVIII or IX 1-5 %) or severe (FVIII or IX <1 %) haemophilia A or B

          -  Submitted written consent to participate in the study

        Exclusion Criteria:

          -  Patients suffering from other bleeding diseases

          -  PWH without written consent

          -  PWH < 18 years of age

          -  Secondary osteoporosis
Male
No healthy subjects accepted to join the trial.
Subject must be at least 18 Years old.


Eligibility (NLI label): Entailment
Patient case (clinical description): The patient is a 38-year-old man with cough and body ache that started 3 days ago.  He had fever and chills at the beginning and has low grade fever at the time of visit. He feels tired and sleepy. His body ache and myalgia get better after using Tylenol. The PCR test for Covid is positive. His vital signs are within normal limits with a body temperature of 37.9 C. There is no lymphadenopathy or white exudates in the pharynx.

Patient's own account: I was feeling really sick the other day, to the point that I showed up at the doctor's office. I was coughing, and my body was hurting for 3 days. I had a fever and chills and felt tired and sleepy. I got better after using Tylenol. They did a PCR Covid test on me, and it was positive! My vitals were normal, and my temperature was 37.9 C. I had no swelling around my neck or white spots on the back of my throat.

Clinical trial: Risk Factors Worsening COVID19 for Out-patient With Home Monitoring

Eligibility criteria:
Inclusion Criteria:

          -  Patient with clinical symptomatology suspecting COVID-19, that is to say: severe
             dyspnea, and/or serious extra pulmonary signs (myalgia, diarrhea, etc.) OR

          -  Patient with clinical symptomatology (cough or dyspnea or fever with ENT signs) AND at
             least one of the following comorbidities: COPD stage 1 or 2 (dyspnea usually absent or
             for marked efforts), Asthma with daily inhaled corticosteroid therapy,
             Immunosuppression or cancer during chemotherapy, Coronary history, Heart failure
             (Stages 2 and 3, dyspnea with moderate or low effort), Obesity (BMI> 30), Type 1 or 2
             diabetes, cirrhosis from Child B, pregnant woman in the 3rd trimester.

          -  Patient with a phone monitoring of at least more than 2 calls, if no aggravation of
             disease.

        Exclusion Criteria:

          -  Person deprived of liberty by judicial or administrative decision

          -  Person being subject to a legal protection measure

          -  Person who expressed opposition to participating in the COVIDADOMEVA study
No condition on gender to be admitted to the trial.
No healthy subjects accepted to join the trial.



Eligibility (NLI label): Contradiction
Patient case (clinical description): A 63-year-old man comes to the clinic for recent unintentional weight loss. The patient also has epigastric discomfort after meals. He has no known medical problems and takes no medications. His blood pressure is 130/75 and pulse rate is 88/min. He is not febrile. Upper endoscopy shows a lesion in the stomach that shows typical features of diffuse-type adenocarcinoma presenting with signet ring cells that do not form glands.

Patient's own account: I went to the clinic because I had been losing so much weight that it was concerning. I'm a 63-year-old guy, and it is something rather unusual. I'm always suffering from stomachache after every meal. I've never been sick, and I don't take any medicine. The doctor took my blood pressure and told me it was 130/75, and my pulse rate was 88/min. I'm not febrile! I also had to do an endoscopy, and they found a lesion in my stomach that shows typical features of stomach cancer. I'm totally devastated...

Clinical trial: Metastatic Gastric Cancer FFCD 03-07

Eligibility criteria:
Inclusion Criteria:

          -  age = 18 years old

          -  patients carrying a adenocarcinoma of the stomach or cardia histologically proven

          -  locally advanced tumour which may not be treated surgically or metastatic tumour

          -  the patients having a stenosante tumour responsible for a disphagy had to have a
             tumoral ablation or a prosthesis or a probe of food,

          -  measurable lesions according to criteria RECIST (specify measurement by spiral scanner
             of largest diameter of with less the one lesion of size higher than 1 cm) or
             appraisable but nonmeasurable (lesions < 1 cm, ascite, pleural effusion...)

          -  general state WHO < 2

          -  absence of insufficiency cardiac or coronary symptomatic

          -  absence of previous chemotherapy other that auxiliary stopped since more than 6 months

          -  filled questionnaires QLQ C30 and STO-22

          -  PNN = 1500/mm3, haemoglobin ≥ 10g/dl, plates= 100 000/mm3

          -  creatinin ≤ 110 micromol/l

          -  bilirubin ≤ 35 micromol/l

        Exclusion Criteria:

          -  disphagy or intestinal obstruction incompatible with a treatment per os or by a probe
             of food

          -  pregnant or nursing woman

          -  previous of cardiac toxicity to the 5FU or to the anthracyclines

          -  radiotherapy less than 3 weeks before inclusion, whatever the site

          -  other evolutionary cancer threatening the short-term life

          -  metastasis cerebral or méningée known (without obligation to seek it)

          -  impossibility of regular follow-up for psychological, social, family or geographical
             reasons
No condition on gender to be admitted to the trial.
No healthy subjects accepted to join the trial.
Subject must be at least 18 Years old.


Eligibility (NLI label): Entailment
Patient case (clinical description): A 61-year-old man comes to the clinic due to nonproductive cough and progressive dyspnea.  The patient's medical conditions include hypertension, hypercholesteremia and peptic ulcer disease.  He smokes 2 packs of cigarettes daily for the past 30 years.  On examination, there are decreased breath sounds and percussive dullness at the base of the left lung.  Other vital signs are normal. Abdomen is soft without tenderness. CT scan shows a left-sided pleural effusion and nodular thickening of the pleura. The plural fluid was bloody on thoracentesis. Biopsy shows proliferation of epithelioid-type cells with very long microvilli.

Patient's own account: I am 61 and I had to go to the clinic because I couldn't stop coughing and I experienced some breath shortness. I suffer from hypertension and cholesterol and I also have a stomach ulcer. I should admit that I've been smoking 2 packs of cigarettes every day for the past 30 years. My doctor told me that my breath in my left lung sounds bad. But he told me that my blood pressure, heart rate, breathing rate and temperature are normal. My belly is also normal. However my X-Rays show some liquid on the left side and a mass where the liquid got hard. The scary thing is that the liquid was bloody when they got it out. They did a biopsy and it showed that I have an increase of epithelioid-type cells with very long microvilli.

Clinical trial: Use of Procalcitonin in the Diagnosis of Pleural Effusion

Eligibility criteria:
Inclusion Criteria:

          -  Clinical diagnosis of pleural effusion

          -  Pleural effusion proved by chest sonography

        Exclusion Criteria:

          -  Conditions for which thoracentesis are contraindicated

          -  Pregnancy
No condition on gender to be admitted to the trial.
No healthy subjects accepted to join the trial.
Subject must be at least 18 Years old.


Eligibility (NLI label): Entailment
Patient case (clinical description): A 66-year-old woman comes to the office due to joint pain in the hands and periodic morning stiffness that lasts less than 15 minutes.  The pain is moderately severe and worsens with daily activity. The patient used Tylenol with minimal relief.  Past medical history is notable for hypertension and hypercholesteremia.  Physical examination shows firm nodules over the distal interphalangeal joints, bilaterally. The patient has pain in her knees as well. The knees are stiff in the morning for less than 30 minutes and become worse with climbing stairs. She has some sensation of bone friction during activity. X-ray shows narrowing of the joint space, subchondral bone sclerosis and osteophyte formation along the joints.

Patient's own account: I'm a 66-year-old woman and I went to my doctor's office because of a bloody joint pain in my hands that has been lasting for a while. The pain comes and go in the morning usually. I feel like a stiffness that last less than 15 minutes. The pain is moderately severe but it gets worse when I'm using my hands. I used Tylenol which helped a little. Apart from that, I suffer from hypertension and high cholesterol. The doctor made me notice that I have bumps around both of my hand joints. I also suffer from my knees and they are also stiff in the morning for around 30 min. It's even worse when I climb up the stairs! I also feel like my bones are rubbing against each other when I'm moving. The X-ray showed that I have narrow joint space, I have sclerosis, and abnormal growths of bone along my joints.

Clinical trial: THERMARTHROSE: Gonarthrosis and Water Cure

Eligibility criteria:
Inclusion Criteria:

          -  ACR criteria: knee pain and one of the tree following conditions: Age > 50 years,
             Morning stiffness< 30 minutes and articular crackling.

          -  osteophytes visible on knee radiography.

          -  knee radiography less than 3 years old: face, schuss, axial of kneecap cliché.

          -  Actual gonarthrosis intensity on Visual Analogic Scale > or = 30mm.

        Exclusion Criteria:

          -  arthrosis limited to the femoro-patellar compartments.

          -  severe depressive syndrome, psychosis.

          -  Thermal cure less than 6 month before.

          -  Contra-indication or predictable inability to tolerate thermal cure.

          -  Profession lied to hydrotherapy.

          -  previous knee treatments:

               -  massage, physiotherapy and acupuncture since less than 1 month;

               -  infiltration since less than 3 months;

               -  NSAI since less than 5 days;

               -  analgesic since less than 12 hours;

               -  modification in the medicinal anti-arthrosis treatment since less than 3 months.
No condition on gender to be admitted to the trial.
No healthy subjects accepted to join the trial.
Subject must be at least 18 Years old.


Eligibility (NLI label): Entailment
Patient case (clinical description): A 50-year-old woman comes to the clinic with intermittent ear discharge and sense of hearing loss on her left ear.  Past medical history is significant for obesity, hyperlipidemia, and diabetes mellitus.  Her medications include Metformin, Atorvastatin and Vit D supplement. Vital signs are normal. BMI is 37. Otoscopy shows a small perforation in the left tympanic membrane and a pearly mass behind the membrane.  Conduction hearing loss is noted in the left ear.  The remainder of the ear, nose, and throat examination is normal.

Patient's own account: I went to the clinic the other day because I had some fluid in my ear and I felt like I could not hear as well as I used to in my left ear. I'm a 50-year-old woman, and I have been obese for a while now. I have diabetes and cholesterol. I take some medication. I take metformin, atorvastatin, and vitamin D supplements. When I was admitted, my vitals were normal. My BMI is 37. When they looked into my ears, they said that my left tympanic membrane was broken and there was some fluid behind the membrane. During the hearing test, they could assess that my left ear suffers from hearing loss. They also performed ear, nose, and throat examinations that turned out to be normal.

Clinical trial: The SeaSHeL National Prospective Cohort Study

Eligibility criteria:
Inclusion Criteria:

          -  Adult patients (male or female) aged over 16 years of age presenting to NHS ENT and
             hearing services with SSNHL AND

          -  Diagnosed with a hearing loss in one or both ears of 30 dB HL or more, over at least 3
             contiguous frequencies, between 250, 500, 1000, 2000, 4000 and 8000 Hz.

        AND

        • Willing and able to provide written informed consent.

        Exclusion Criteria:

          -  Patients with mixed or conductive hearing loss (CHL). CHL will be defined as a 'true'
             air-bone gap of 15 dB HL or more in 3 or more contiguous frequencies between 500,
             1000, 2000, 4000 Hz.
No condition on gender to be admitted to the trial.
Accepts Healthy Volunteers
Subject must be at least 16 Years old.


Eligibility (NLI label): Contradiction
Patient case (clinical description): A 50-year-old woman comes to the clinic with intermittent ear discharge and sense of hearing loss on her left ear.  Past medical history is significant for obesity, hyperlipidemia, and diabetes mellitus.  Her medications include Metformin, Atorvastatin and Vit D supplement. Vital signs are normal. BMI is 37. Otoscopy shows a small perforation in the left tympanic membrane and a pearly mass behind the membrane.  Conduction hearing loss is noted in the left ear.  The remainder of the ear, nose, and throat examination is normal.

Patient's own account: I went to the clinic the other day because I had some fluid in my ear and I felt like I could not hear as well as I used to in my left ear. I'm a 50-year-old woman, and I have been obese for a while now. I have diabetes and cholesterol. I take some medication. I take metformin, atorvastatin, and vitamin D supplements. When I was admitted, my vitals were normal. My BMI is 37. When they looked into my ears, they said that my left tympanic membrane was broken and there was some fluid behind the membrane. During the hearing test, they could assess that my left ear suffers from hearing loss. They also performed ear, nose, and throat examinations that turned out to be normal.

Clinical trial: Governance of Diabetes Management in Non-specialistic Hospital Settings

Eligibility criteria:
Inclusion Criteria:

          -  patients with type 2 or type 1 diabetes or stress hyperglycemia

        Exclusion Criteria:

          -  age <18,

          -  patients hospitalized for diabetic complications: ketoacidosis, hyperosmolar syndrome,
             hypoglycemic coma, pregnant diabetics or gestational diabetes
No condition on gender to be admitted to the trial.
No healthy subjects accepted to join the trial.
Subject must be at least 18 Years old.


Eligibility (NLI label): Entailment
Patient case (clinical description): A 43-year-old woman, gravida 3 para 3, comes to the clinic complaining of recently painful menstrual cycles.  The patient's last menstrual period was 2 weeks ago. Urine β-hCG is negative. Menarche was at age 12, and menstrual periods occur every 28 days and lasts for 5 days.  She is sexually active with her husband and does not have pain with intercourse. BMI is 23 kg/m2 and Vital signs are normal.  On physical examination, the uterus is uniformly enlarged and tender. She is candidate for hysterectomy with the diagnosis of adenomyosis.

Patient's own account: I'm 43, and I paid a visit to my doctor because my last few periods were insanely painful. My last periods were 2 weeks ago. I already had three pregnancies that gave me the three lovely children. I did a urine test to check for potential pregnancy, and it came back negative. I started to have my periods at the age of 12, and I have been pretty regular with periods every 28 days for 5 days. I'm sexually active with my husband and I do not have any pain when we have sex. My BMI is 23 and my vitals were normal. The doctor performed a physical exam and found that my uterus was tender and enlarged. She proposed me a hysterectomy and diagnosed me with adenomyosis.

Clinical trial: LESS-TLH Versus LESS-LAVH

Eligibility criteria:
Inclusion Criteria:

          -  women with indication for hysterectomy for a supposed benign uterine disease

          -  women with an age of 18 years or older

          -  women who were not pregnant at the time of presentation

          -  women who were appropriated medical status for laparoscopic surgery (American Society
             of Anesthesiologists Physical Status classification 1 or 2)

        Exclusion Criteria:

          -  uterine volume > 18 weeks of gestation by pelvic examination

          -  suspicion of malignancy

          -  pelvic organ prolapse > stage 1 according to POP-Q classification

          -  inability to understand and provide written informed consent.
Female
No healthy subjects accepted to join the trial.
Subject must be at least 18 Years old.
Subject must be at most 75 Years

Eligibility (NLI label): Entailment
Patient case (clinical description): A 32-year-old woman comes to the hospital with vaginal spotting.  Her last menstrual period was 10 weeks ago. She has regular menses lasting for 6 days and repeating every 29 days. Medical history is significant for appendectomy and several complicated UTIs. She has multiple male partners, and she is inconsistent with using barrier contraceptives. Vital signs are normal.  Serum β-hCG level is 1800 mIU/mL, and a repeat level after 2 days shows an abnormal rise to 2100 mIU/mL.  Pelvic ultrasound reveals a thin endometrium with no gestational sac in the uterus.

Patient's own account: I just turned 32 and last morning I woke up with strange blood stains on my underwear. My last periods were more than 2 months ago, which is unusual for me because I used to have regular periods lasting for 6 days every 29 days, more or less. I had several UTIs in the past. I also had appendicitis. I'm currently seeing several men and, to be honest, some of them do struggle to wear a condom. I went to the hospital to check myself up and they told me that my vitals were normal. I also had a blood test on Monday, and my β-hCG level was 1800 mIU/mL, and then on Wednesday, it went up to 2100 mIU/mL. The gynecologist also did an ultrasound and she told me that, hopefully, there was no ovule.

Clinical trial: Antagonist/Letrozole in Poor Responders

Eligibility criteria:
Inclusion Criteria:

          -  at least one previous failed IVF cycle in which three or fewer follicles with a mean
             diameter of 16 mm were achieved, and/or

          -  serum E2 level measured on the day of hCG administration was ≤500 pg/ml

        Exclusion Criteria:

          -  day 3 serum FSH level ≥12 mIU/mL

          -  there is no age limit
Female
Accepts Healthy Volunteers



Eligibility (NLI label): Contradiction